Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYAI NASDAQ:HYPD NASDAQ:IMA OTCMKTS:IMUC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.99+0.6%$0.95$0.71▼$2.20$36.01M0.9482,984 shs70,238 shsHYPDHyperion DeFi$10.25+17.1%$9.15$0.85▼$47.33$58.37M2.51.93 million shs1.56 million shsIMAImageneBio$8.91-3.0%$14.73$7.95▼$23.28$35.82M0.4916,973 shs12,352 shsIMUCEOM Pharmaceutical$0.09$0.08$0.01▼$0.21$11.23M0.067,903 shs1,317 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International+1.63%+3.06%+4.67%-1.92%-20.90%HYPDHyperion DeFi+35.03%+47.55%+17.29%+159.64%-80.64%IMAImageneBio-1.08%-31.21%-37.36%-45.30%-54.95%IMUCEOM Pharmaceutical0.00%+45.57%-5.13%-17.63%-47.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.99+0.6%$0.95$0.71▼$2.20$36.01M0.9482,984 shs70,238 shsHYPDHyperion DeFi$10.25+17.1%$9.15$0.85▼$47.33$58.37M2.51.93 million shs1.56 million shsIMAImageneBio$8.91-3.0%$14.73$7.95▼$23.28$35.82M0.4916,973 shs12,352 shsIMUCEOM Pharmaceutical$0.09$0.08$0.01▼$0.21$11.23M0.067,903 shs1,317 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International+1.63%+3.06%+4.67%-1.92%-20.90%HYPDHyperion DeFi+35.03%+47.55%+17.29%+159.64%-80.64%IMAImageneBio-1.08%-31.21%-37.36%-45.30%-54.95%IMUCEOM Pharmaceutical0.00%+45.57%-5.13%-17.63%-47.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYAIDyadic International 3.00Buy$6.00507.90% UpsideHYPDHyperion DeFi 2.00Hold$2.00-80.49% DownsideIMAImageneBio 2.50Moderate Buy$35.50298.43% UpsideIMUCEOM Pharmaceutical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMUC, HYPD, DYAI, and IMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DYAIDyadic InternationalCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy7/25/2025IMAImageneBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$25.00 ➝ $23.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYAIDyadic International$3.49M10.23N/AN/A$0.08 per share12.34HYPDHyperion DeFi$44.44K1,313.60N/AN/A($695.52) per share-0.01IMAImageneBio$9.16M3.91N/AN/A$31.33 per share0.28IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYAIDyadic International-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)HYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%-876.25%-181.67%N/AIMAImageneBio-$49.23M-$7.68N/AN/AN/AN/A-23.94%-21.62%N/AIMUCEOM Pharmaceutical-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALatest IMUC, HYPD, DYAI, and IMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million8/13/2025Q2 2025HYPDHyperion DeFiN/A-$2.50N/A-$2.50N/AN/A7/24/2025Q2 2025IMAImageneBio-$0.14-$0.06+$0.08-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYAIDyadic InternationalN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYAIDyadic International5.402.022.02HYPDHyperion DeFi0.200.910.91IMAImageneBioN/A13.5213.52IMUCEOM PharmaceuticalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYAIDyadic International27.95%HYPDHyperion DeFi25.84%IMAImageneBio75.00%IMUCEOM PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipDYAIDyadic International29.50%HYPDHyperion DeFi10.86%IMAImageneBio5.94%IMUCEOM Pharmaceutical3.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYAIDyadic International736.19 million25.51 millionOptionableHYPDHyperion DeFi405.70 million5.08 millionNo DataIMAImageneBio704.02 million3.78 millionNot OptionableIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionableIMUC, HYPD, DYAI, and IMA HeadlinesRecent News About These CompaniesQ32 Bio Inc. R (DB0.BE)January 15, 2025 | finance.yahoo.comImmunoCellular Therapeutics, Ltd. (IMUC)January 5, 2024 | uk.finance.yahoo.comEOM Pharmaceutical Holdings Inc.December 29, 2023 | wsj.comEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613November 7, 2023 | finance.yahoo.comAAO 2023: Apellis unveils data from GALE extension studyNovember 4, 2023 | ophthalmologytimes.comOIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 YearsNovember 4, 2023 | markets.businessinsider.comImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives RevenuesNovember 3, 2023 | msn.comOramed Pharmaceuticals Inc ORMPNovember 1, 2023 | morningstar.comMAnalyst Ratings for Olema PharmaceuticalsOctober 11, 2023 | markets.businessinsider.comEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilSeptember 6, 2023 | finance.yahoo.comQ2 2023 PAVmed Inc Earnings CallAugust 17, 2023 | uk.finance.yahoo.comEOM Pharmaceuticals shelves plans to uplist shares, raise $15MAugust 3, 2023 | msn.comSYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over ...July 30, 2023 | bakersfield.comBAcumen Pharmaceuticals Announces Proposed Public Offering of Common StockJuly 17, 2023 | benzinga.comFDA rejects Amneal's Parkinson's drugJuly 5, 2023 | beckershospitalreview.comBAmneal Pharmaceuticals: FDA Requests Additional Information on IPX203 IngredientJuly 3, 2023 | marketwatch.comBishop Rehabilitation & Nursing Names Their June 2023 EOMJune 26, 2023 | patch.comAmneal Pharmaceuticals Gets FDA Approval for Injectable Tumor TreatmentJune 14, 2023 | marketwatch.comTrade commission fights Amgen's $28B purchase of Horizon TherapeuticsMay 16, 2023 | msn.comOramed: Q1 Earnings SnapshotMay 12, 2023 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUC, HYPD, DYAI, and IMA Company DescriptionsDyadic International NASDAQ:DYAI$0.99 +0.01 (+0.63%) As of 01:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Hyperion DeFi NASDAQ:HYPD$10.25 +1.50 (+17.14%) As of 01:33 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.ImageneBio NASDAQ:IMA$8.91 -0.28 (-3.05%) As of 01:23 PM EasternImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.EOM Pharmaceutical OTCMKTS:IMUC$0.09 0.00 (0.00%) As of 11:38 AM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
